In its update, GSK reported a 17% rise in speciality medicines across its HIV, cancer and respiratory business to £2.93 billion, with good performances for long-acting HIV drugs, severe asthma therapy ...

AZ has already thrown down a marker for its tougher stance on Europe with an earlier decision to abandon a $560 million vaccine manufacturing plant initially intended for the UK, sparking speculation ...